Synovus Financial’s Halozyme HALO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $5.31M | Sell |
72,350
-5,609
| -7% | -$373K | 0.06% | 188 |
|
|
2025
Q2 | $4.06M | Sell |
77,959
-4,002
| -5% | -$228K | 0.05% | 226 |
|
|
2025
Q1 | $5.23M | Buy |
81,961
+3,361
| +4% | +$195K | 0.07% | 178 |
|
|
2024
Q4 | $3.76M | Sell |
78,600
-1,990
| -2% | -$102K | 0.05% | 233 |
|
|
2024
Q3 | $4.61M | Sell |
80,590
-7,612
| -9% | -$436K | 0.05% | 228 |
|
|
2024
Q2 | $4.62M | Sell |
88,202
-54
| -0.1% | -$2.37K | 0.06% | 197 |
|
|
2024
Q1 | $3.59M | Buy |
88,256
+9,760
| +12% | +$366K | 0.05% | 239 |
|
|
2023
Q4 | $2.9M | Buy |
78,496
+20,713
| +36% | +$780K | 0.04% | 265 |
|
|
2023
Q3 | $2.21M | Sell |
57,783
-2,405
| -4% | -$98.5K | 0.03% | 322 |
|
|
2023
Q2 | $2.17M | Buy |
60,188
+4,134
| +7% | +$141K | 0.02% | 326 |
|
|
2023
Q1 | $2.14M | Sell |
56,054
-22,821
| -29% | -$1.07M | 0.02% | 325 |
|
|
2022
Q4 | $4.49M | Buy |
78,875
+1,957
| +3% | +$100K | 0.05% | 199 |
|
|
2022
Q3 | $3.04M | Buy |
76,918
+23,393
| +44% | +$1.03M | 0.04% | 244 |
|
|
2022
Q2 | $2.35M | Sell |
53,525
-24,058
| -31% | -$1.04M | 0.03% | 285 |
|
|
2022
Q1 | $3.1M | Buy |
77,583
+8,014
| +12% | +$285K | 0.03% | 256 |
|
|
2021
Q4 | $2.8M | Buy |
69,569
+8,169
| +13% | +$305K | 0.03% | 270 |
|
|
2021
Q3 | $2.5M | Buy |
61,400
+10,181
| +20% | +$426K | 0.03% | 271 |
|
|
2021
Q2 | $2.32M | Buy |
51,219
+2,001
| +4% | +$88.6K | 0.02% | 281 |
|
|
2021
Q1 | $2.06M | Sell |
49,218
-1,803
| -4% | -$82.3K | 0.02% | 269 |
|
|
2020
Q4 | $2.17M | Sell |
51,021
-8,239
| -14% | -$296K | 0.03% | 258 |
|
|
2020
Q3 | $1.55M | Buy |
59,260
+8,913
| +18% | +$248K | 0.02% | 289 |
|
|
2020
Q2 | $1.35M | Sell |
50,347
-12,271
| -20% | -$277K | 0.02% | 289 |
|
|
2020
Q1 | $1.12M | Buy |
62,618
+2,021
| +3% | +$38.4K | 0.02% | 347 |
|
|
2019
Q4 | $1.08M | Buy |
60,597
+2,194
| +4% | +$38K | 0.01% | 328 |
|
|
2019
Q3 | $898K | Buy |
58,403
+2,375
| +4% | +$39.1K | 0.01% | 345 |
|
|
2019
Q2 | $965K | Buy |
56,028
+2,482
| +5% | +$40K | 0.01% | 345 |
|
|
2019
Q1 | $862K | Buy |
53,546
+5,620
| +12% | +$91.1K | 0.01% | 353 |
|
|
2018
Q4 | $702K | Buy |
47,926
+12,972
| +37% | +$207K | 0.01% | 368 |
|
|
2018
Q3 | $632K | Buy |
34,954
+1,762
| +5% | +$30.9K | 0.01% | 419 |
|
|
2018
Q2 | $560K | Sell |
33,192
-7,027
| -17% | -$133K | 0.01% | 421 |
|
|
2018
Q1 | $787K | Buy |
40,219
+2,121
| +6% | +$41.1K | 0.01% | 354 |
|
|
2017
Q4 | $773K | Sell |
38,098
-305
| -0.8% | -$5.61K | 0.01% | 344 |
|
|
2017
Q3 | $664K | Buy |
38,403
+2,247
| +6% | +$30.4K | 0.01% | 362 |
|
|
2017
Q2 | $463K | Buy |
36,156
+10,596
| +41% | +$142K | 0.01% | 426 |
|
|
2017
Q1 | $334K | Buy |
25,560
+6,075
| +31% | +$76.8K | 0.01% | 440 |
|
|
2016
Q4 | $191K | Sell |
19,485
-3,073
| -14% | -$33.7K | ﹤0.01% | 512 |
|
|
2016
Q3 | $272K | Buy |
+22,558
| New | +$231K | 0.01% | 441 |
|
Other funds holding HALO
SCM
Synovus Financial's HALO Position: Q3 2025 in Review
Synovus Financial reduced its Halozyme (HALO) stake by 7.2% in Q3 2025, selling an estimated $373K and leaving 72,350 shares worth $5.31M. The position accounts for 0.06% of the portfolio, ranked #188.
Synovus Financial first reported a position in HALO in Q3 2016 and has held it in 37 quarters since. 602 funds tracked by Wall St. Rank hold HALO as of Q3 2025.
- Synovus Financial held 72,350 shares of Halozyme worth $5.31M as of Q3 2025.
- Synovus Financial sold 5,609 Halozyme shares in Q3 2025, an estimated $373K.
- Halozyme made up 0.06% of Synovus Financial's portfolio in Q3 2025, its #188 holding.
- Synovus Financial first reported a position in Halozyme in Q3 2016 and has held it in 37 quarters since.
- 602 funds tracked by Wall St. Rank held Halozyme as of Q3 2025.
Based on Synovus Financial's 13F filing for Q3 2025, filed 7 Nov 2025.